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Abstract
Pharmacologic treatment for tuberculosis is widely available in developing nations, and is
often financed by the governments of these countries. Treatment however can be highly toxic
and require a lengthy duration of therapy. There are now many strains of tuberculosis that
are drug resistant. People in impoverished nations frequently cannot afford to pay for
transportation to and from treatment facilities. Research and development of new
tuberculosis drugs is necessary given the presence of resistance and toxicity of the existing
drugs. Newer agents that require shorter treatment duration with decreased toxicity and
increased efficacy are most desirable and needed in developing nations.
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Tuberculosis In Developing Nations:
Why New Drugs Need To Be Researched And Developed
The rate of new tuberculosis (TB) cases is on the rise, even in light of better
diagnostic methods and treatment regimens. According to Alteri, Xicohténcatl-Cortes, Hess,
Caballero-Olín, Girón, & Friedman, tuberculosis remains the most devastating bacterial
cause of human mortality. One-third of the world’s population is infected with the TB
mycobacterium (Kumar, Malhotra, Goswami, & Bamezai, 2003), and two million people die
from the disease every year (Salomon Lloyd-Smith, Getz, Resch, Sánchez, Porco, et al,
2006). This is a significant problem worldwide. Existing drugs have a long course of
therapy, and most are hepatotoxic. In addition, drug-resistant tuberculosis cases are
increasing. New TB drugs need to be developed to stop this disease from becoming an
epidemic.
Bacteria Mycobacterium tuberculosis
Tuberculosis (TB) is a disease caused primarily by the Mycobacterium tuberculosis
bacterium. M. tuberculosis is an acid-fast mycobacterium that grows very slowly. Its cell
wall consists primarily of lipids and allows the bacterium to resist disinfectants, antiseptics,
drying out, and other environmental hazards. Because of its structure, M. tuberculosis is
difficult to kill.
There are several types of TB infections, each named mainly for the location of the
infection. Pulmonary TB is the most common and also the most deadly form of TB (Kumar,
et al., 2003). For simplification purposes, in this paper “TB” and “tuberculosis” refer to
pulmonary tuberculosis unless otherwise specified.
In pulmonary TB, the M. tuberculosis bacteria enter the body through the lungs by
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inhalation. If an individual is healthy, the immune system initially recognizes the bacteria as
intruders. However, TB bacteria have a surprise feature, one that makes TB a difficult, if not
impossible, opponent for an immune system to conquer. M. tuberculosis possesses the
ability to bypass the defense mechanisms of the human immunologic system. It has the
“ability to arrest phagolysosome biogenesis, avoid direct cidal mechanisms in macrophages,
and block efficient antigen processing and presentation” (Deretic Singh, Master, Harris,
Roberts, Kyei, et al., 2006 p. 719).
The initial detection of M. tuberculosis by the immune system triggers the body’s
natural defenses, including the mass migration of macrophages to the site of infection. These
macrophages attempt to contain the infection by building walls of cells around the invaders,
enclosing them in capsule-like lesions called tubercles (Tortora, Funke, & Case, 2004). In
the rush to contain the infection, macrophages are encapsulated along with the tuberculosis
bacilli. They are left to destroy all the intruders inside the capsule, but this does not occur.
After the tubercles have been formed, M. tuberculosis acts as a parasite, evading detection by
entering into and living inside the macrophages, specifically in phagosomes (immature
phagolysosomes). Phagosomes normally mature into phagolysosomes, but this process does
not occur in immune cells invaded by the tuberculosis mycobacterium because M.
tuberculosis produces two substances – a lipid and an enzyme – both of which prevent the
conversion of its host phagosome into a phagolysosome (Deretic et al., 2006). Since
phagolysosomes are a major component of the body’s immune response, the ability of M.
tuberculosis to evade detection in this way defeats the body’s natural defense system against
TB, giving it time to multiply. When the bacilli are still encapsulated, the tuberculosis
infection is said to be latent. A TST or blood test will indicate exposure, but since the
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bacteria are contained within the tubercles, they are not present in sputum; therefore a
sputum smear would test negative.
Over time, the tubercle lesions become calcified. They are then called Ghon
complexes and will appear on X-rays and CT scans. The tuberculosis bacilli remain alive
and replicate in these Ghon complexes, waiting until their host’s immune system becomes
deficient. The capsules then burst open, releasing TB bacilli into the body’s lungs,
cardiovascular system, and lymphatic system. As soon as the TB bacilli break out of the
Ghon complexes, the infection is classified as active, or miliary TB, because of the tiny
millet seed-sized tubercles that form in the tissues. Because it is fighting a weakened
immune system, M. tuberculosis defeats the remaining immune defenses and continues to
multiply unhindered. Unlike latent TB, active TB is symptomatic. Weight loss, weakness,
and coughing up blood are classic signs of active TB infection. The disease was formerly
known as “consumption” because the infected person became weaker and weaker, lost
weight, and simply seemed to be consumed by the illness (Tortora, Funke, & Case, 2004).
One reason that TB is so hard to treat is that it avoids detection by the body’s
macrophages by living and replicating inside those very macrophages. Scientists are still
puzzled by exactly how the mycobacterium accomplishes this (Alteri, et al., 2007). Alteri, et
al. are part of the search for the answer. In the past, scientists believed that mycobacteria did
not produce pili. However, Alteri, et al. discovered that TB mycobacteria do indeed produce
pili that help them attach to macrophages. In their study, they found that 60% of tuberculosis
patients’ serum samples tested positive for Mycobacteria tuberculosis pili (MTP), but none
of the non-tuberculosis infected serum samples did (Alteri, et al., 2007).
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MTP are very similar to the pili-like structures produced by the highly virulent
bacteria Escherichia coli and Salmonella enterica. Despite that similarity, MTP are not easily
broken down, whereas the pili of E. coli and S. enterica are (Alteri, et al., 2007). MTP are
polymeric, hydrophobic, and protein-based. They bind to laminin, an extracellular matrix
protein which is a major component of human cellular basement membranes. Although
suspected but not proven to be the case with MTP, other bacterial pili are responsible for
allowing bacteria to agglutinate erythrocytes, aggregate bacteria, form biofilm, adhere to
cells, and form colonies on mucosal surfaces. All of these functions are related to the
virulence of bacteria. MTP allows M. tuberculosis to attach to, enter, and colonize first
macrophages and then other tissues. If scientists could medically target bacterial pili, they
could greatly decrease, if not completely destroy, the TB bacteria’s pathogenicity. For this
reason, pili have been a focus of vaccine research and development (Alteri, et al., 2007).
M. bovis is a bacterium similar to M. tuberculosis that also produces tuberculosis. M.
bovis infection is acquired by drinking unpasteurized milk. Unlike M. tuberculosis, M. bovis
is not transmissible from person to person. The tubercles found in M. bovis infection are
normally found in the bones and lymphatic system rather than in the lungs (Tortora, Funke,
& Case, 2004).
Drug resistance is a major problem in the treatment of Mycobacterium tuberculosis
infection. This problem exists due to multiple reasons. First, the treatment of M. tuberculosis
is prolonged (six months to a year or longer), because M. tuberculosis grows slowly. Since
treatment is prolonged, there is more time for the bacteria to mutate and develop drugresistant strains. Secondly, patient compliance decreases the longer the duration of treatment
(Lenhe 2007). There are two major classifications for resistant TB strains; multi drug
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resistant (MDR) and extensively drug resistant (XDR) TB. Multiple drug resistant (MDR)
TB is resistant to two or more TB drugs, usually the first-line drugs Isoniazid and Rifampin.
Shah, Wright, Bai, Barrera, Boulahbal, Martín-Casabona, et al. define extensively drug
resistant (XDR) TB as MDR-TB with added resistance to three or more of the second-line
TB drugs. The World Health Organization’s (WHO) guidelines call for MDR-TB to be
treated with four or more different TB drugs to which that particular strain is susceptible.
However, since XDR TB is, by definition, resistant to three or more second line drugs, and
since there are only six classes of second-line drugs, effective treatment of XDR TB is, by
WHO standards, absolutely impossible to treat with existing resources.
Screening Methods
Several tests are used to determine TB exposure. The tuberculin skin test (TST) is an
intradermal injection of purified protein derivative (PPD), which is an M. tuberculosis
antigen. If the patient has been infected with TB and has a functional immune system, there
will be a local reaction (hardness) around the injection site. In an immunocompromised
patient (such as one with AIDS – acquired immune deficiency syndrome), a smaller reaction
size is adequate to diagnose exposure to TB. This is because the immunocompromised
patient’s immune system cannot react as well as a healthy person’s would, producing a
weaker reaction. A PPD will not test positive unless a person has been infected for six weeks
or more (Pagana & Pagana, 2007).
Chest radiography is a very accurate way to diagnose TB, and is often done to check
for tubercles in the lungs after a positive PPD. A chest x-ray cannot distinguish between
latent and active TB. It also will not be positive (show tubercles) in the early stages of the
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disease, because there has not been enough time for the macrophages to form tubercles
around the bacteria and calcify into Ghon complexes.
The QuantiFeron-TB Gold blood test is another test to determine TB exposure. This
test uses a blood sample to determine TB exposure. It is equally as effective as the TST,
results are known more rapidly (24 hours), and it only requires one doctor visit rather than
the two needed for the TST. This test is not as widely available as other tests (Lenhe 2007).
The sputum smear is one of the quickest, most accurate methods available for
diagnosing active TB infection. The process is simple and painless for the patient. A sputum
sample is taken, which is transferred to a slide, stained with acid-fast dye, and viewed under
a microscope to note the presence of mycobacteria bacilli. The problem with the sputum
smear is that it can only diagnose active pulmonary TB, which means that it will test negative
if the infection is latent or resides anywhere but the lungs.
DOTS, formerly simply an acronym for “directly observed therapy, short-course”, is
the WHO’s international standard for TB treatment. It was implemented as standard care in
TB treatment because of patient non-adherence. In DOTS, a healthcare worker observes the
patient when they are taking the drugs to ensure that the medicine is taken. Now, DOTS
refers not only to the direct observation aspect of TB treatment, but also to the world health
organization’s (WHO) entire public health strategy for TB. It includes directly observed
therapy, a chemotherapy and first-line drug regimen, use of sputum-smear microscopy to
diagnose TB, supportive measures taken for patients on long-term (6-9 month) therapy, and
records of drug supplies and distribution.
Since its institution, DOTS therapy has been very successful, with cure rates of over
80% (Salomon et al., 2006). However, DOTS only catches active cases of TB. Everyone
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who comes to a clinic, with symptoms of TB (persistent coughing, etc.) is examined and
sputum-smear tested for the disease. This works well to test for active cases, but since in
latent TB the sputum contains no TB bacteria, this method of screening if used alone is
ineffective in the eradication of tuberculosis.
Many different immune-based tests are being sold commercially in developing
nations. These test serum antibodies, antigens, and immune complexes, for evidence of TB
infection. It would seem that these would be reliable diagnostic tests. They are much faster
and simpler than sputum smears. A systematic review of the literature was performed,
which found that no commercial immune-based test is accurate enough to replace the sputum
smear as a diagnostic tool for TB. Also, none of them could accurately diagnose TB in
children or patients co-infected with human immunodeficiency virus (HIV). A concern is
that since the commercial tests are sold widely in developing nations, they will distract
resources from the more accurate sputum smear test (Steingart, Henry, Laal, Hopewell,
Ramsay, & Menzies, et al., 2007).
In addition to traditional methods of TB screening, some scientists are thinking
outside the box when it comes to checking for the disease. Scientists in Morogoro, Tanzania,
are attempting to use rats in the detection of TB in sputum samples. The rats are trained to
recognize the smell of TB mycobacterium in human sputum. These researchers have already
trained rats to sniff out landmines, so with their keen sense of smell, the rats are capable of
such work. With their ability to sniff through over 200 samples an hour, the rats are capable
of working much faster than human lab technicians, who can only work through about 20
samples a day. Early results indicate that with their accurate sense of smell, the rats also find
fewer false positives (Holden, 2004). If this method of TB detection proves reliable, the
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diagnostic process would be faster and more accurate than technician-checked sputum
smears.
A bacterial culture is the gold standard for TB testing. A sputum sample is put on a
culture medium and screened every 24 hours for growth. Once there is enough bacterial
growth, it is checked by microscope to test what kind of bacteria it is. If a sputum sample
grows M. tuberculosis, then the patient certainly has the disease. However, it is a lengthy
process because M. tuberculosis grows extremely slowly.
MDR and XDR TB are difficult to detect. Testing for resistance to second-line drugs
is not as available in developing countries as testing for resistance to first-line drugs. Shah,
et al. tested TB isolates from laboratories that had received samples from forty-eight
countries. Out of 17000 samples, almost 20% were MDR and almost 10% were XDR. They
found XDR TB in every region of the world that was tested in the study. Since XDR TB is
untreatable by WHO standards, it is a considerable threat to public health worldwide. If
WHO’s DOTS guidelines are not strictly adhered to, the incidence of XDR TB will greatly
increase (Shah, et al., 2007).
Tuberculosis Drugs
Isoniazid is the drug of choice in TB treatment. It is more effective, less toxic,
cheaper, and easier to use than other TB drugs. Isoniazid is selective to M. tuberculosis, and
can kill the bacilli at concentrations much lower than it would take to kill gram positive or
negative bacteria. It is bactericidal when mycobacteria are actively dividing, but
bacteriostatic when they are not. For this reason, it is more effective during the first phase of
treatment, when active TB is being defeated. A problem with Isoniazid is that the TB bacilli
spontaneously mutate during treatment, and can develop resistance. If multiple drugs are
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used to treat tuberculosis, resistant strains of TB will not emerge in that patient. When
treating active TB, Isoniazid must always be administered with one or more other anti-TB
drugs to prevent resistance, but when treating latent TB it can be used alone. Isoniazid has
many undesirable side effects. It is hepatotoxic, and when its use causes vitamin B6
deficiency, peripheral neuritis results- manifested by tingling, burning, numbness,
clumsiness, and unsteadiness. Vitamin B6 deficiency is easily treated with administration of
vitamin B6. However, in a developing nation, enough of the vitamin may not be available
because of an already malnourished diet, and vitamin pills may not be available at all (Lenhe
2007).
Rifampin is another first-line drug, and it is similar to Isoniazid in effectiveness. It is
well tolerated, but does have some strange, adverse effects – it causes sweat, tears, and other
body fluids to turn reddish-orange. Like Isoniazid it is hepatotoxic, and a combination of
those two and other TB drugs, almost all of which are hepatotoxic, is especially dangerous
for the liver. Unfortunately, this combination is standard in TB treatment. Rifampin causes
the body to accelerate its metabolism of many drugs, which is important because this
decreases the effectiveness of HIV drugs. A first-line TB drug that does not increase the
metabolism of HIV drugs is Rifabutin (Lenhe, 2007).
Since they are less effective and more toxic than their first-line counterparts, secondline TB drugs are only used when mycobacterium are found to be resistant to the first-line
drugs. To prevent further drug resistance, second-line drugs are always used in conjunction
with one or more first-line drugs. In addition to hepatotoxicity, many second-line drugs are
nephrotoxic, and all have very unpleasant side effects. Several cause severe gastrointestinal
(GI) disturbances; one causes balance disturbance and hearing loss; and one even crosses the
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blood-brain barrier entering the cerebrospinal fluid (CSF). This action can cause psychoses,
seizures, depression, and other central nervous system (CNS) effects. Due to their toxicities,
caution must be exercised when using these drugs to treat patients (Lenhe 2007).
R207910, a diarylquinolone, is one of several new TB drugs that were recently
discovered. This drug is still being tested, but researchers say that it is highly promising for
the treatment of TB and even MDR TB. It is bactericidal and bacteriostatic, so it would be
able to treat both active and latent TB infection (Biava, Porretta, Deidda, & Pompei, 2006).
Laboratory studies done on mice concluded that when R207910 replaced one of the drugs in
the normal 3-drug cocktail (Isoniazid, Rifampin, and Pyrazinamide), it worked twice as fast
as the conventional drug regimen. They found that it also treats MDR TB. Mycobacteria do
develop resistance to R207910, so it would have to be given in conjunction with other TB
drugs, but it could significantly shorten treatment time (Cohen, 2004). As of October, 2007,
it was still in the testing stage, so whether it will be effective throughout the rigorous human
trials and be affordable for people in developing countries remains to be seen (Barry &
O’Conner, 2007).
Tuberculosis Treatment
Drug therapy for active TB must use at least two drugs. The chance of M. TB
mutating so that it is resistant to one drug is one in 108. Since there are generally this many
bacteria in an infected individual, the likelihood of drug resistance development is very high.
The chance of a single bacterium developing resistance to two drugs is 1016. The likelihood
of resistance developing with those odds is nil if the treatment regimen is completed.
Therefore, if TB is treated with two or more drugs, even if a bacterium develops resistance to
one of the drugs used in treatment, the other would kill it, eliminating drug resistance in that
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individual (Lenhe 2007). DOTS treatment requires at least two drugs, but usually three or
more are used as a precaution.
First-line drugs are used for six months in patients who have never before been
treated. Second-line drugs are used for 8 months to two years in patients who have
contracted a resistant strain of TB. (TB must be treated for 12-24 months after the sputum is
no longer positive for the bacilli.) In theory, when all of WHO’s treatment guidelines are in
place, cure rates for TB can be up to 90%. However, the emergence of multi-drug resistant
TB lowers this cure rate. (Lenhe 2007; Espinal & Dye, 2005; Nathanson, et al., 2006).
The existence of multi-drug resistant bacteria necessitate the testing of the bacilli of
each infected individual for drug susceptibility. These tests can take as long as 4-6 weeks.
Meanwhile, the patient is started on a combination of 4 drugs (usually Isoniazid, Rifampin,
Pyrazinamide, and Ethambutol). This first phase (the induction phase) is to eliminate the
active and multiplying bacteria and usually lasts two months. If resistance is suspected or
discovered, the patient is started into the second phase (continuation phase) and up to seven
other drugs are added to the regimen (Lenhe 2007). The continuation phase lasts four
months, and Isoniazid and Rifampin are used (Lenhe 2007). The goal is to kill the remaining
bacilli that are dormant in the tubercles, so that they cannot re-emerge and cause active
infection.
Any TB strain that is resistant to second-line drugs is very difficult, if not impossible,
to treat with existing drugs. Shah, et al. says, “resistance to TB drugs results primarily from
non-adherence by patients, incorrect drug prescribing by providers, poor quality of drugs, or
erratic supply of drugs.” Each of these problems is rampant in third-world countries. It is no
surprise that drug-resistant TB is rife in those countries as a result (Shah, et al., 2007).
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Suarez, et al. did a study on the cost-effectiveness of using second-line drugs on
chronic TB in Peru. They found that there was an increase in the number of patients who
were cured when second-line drugs were used on MDR TB. However, they also found that
treatment with second-line drugs was less cost-effective than with first-line drugs, and using
second-line drugs also prolonged treatment, resulting in a high dropout rate for the study.
Findings concluded that only half of the subjects were cured (Suarez, et al. 2002).
This study gives a glimpse of one facet of the problem of MDR TB. It is a problem
that perpetuates itself. Drug-resistant TB is created when tuberculosis treatment is not
completed, which, because of long treatment time, occurs frequently. Non-completion can
happen for a variety of reasons, such as when patients stop taking the medication because
they forget, because they begin to feel better after defeating the active infection, or because
the side effects are so unpleasant. Another problem, especially in developing countries, is
that the supply of TB treatment drugs is unreliable and only intermittently available (Suarez,
et al. 2002).
In 2006, Eva Nathanson, et al. completed a study on the treatment of MDR TB in five
developing countries. Half of the subjects were resistant to both first-and second-line TB
drugs. Nathanson, et al. found an average cure rate of 70%, with a higher cure rate among
those who had never been treated than those who had been treated previously. Patients
involved in the study received DOTS treatment, and in some of the countries studied, also
received free transportation, food and money incentives to participate in the DOTS, and
housing and financial support if needed. Nathanson, et al. concluded that the treatment of
MDR TB could be as effective in developing countries as in wealthier nations. However, in
one country, default rates (the number of patients who discontinued treatment for two or
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more consecutive months) were low because many of the subjects were imprisoned and thus
were literally captive participants. The patients in another country were hospitalized during
treatment, which would also falsely lower default rates because it cuts out real-life factors
such as transportation costs and lodging in the town where DOTS treatment is offered. In the
Philippines, for example, default rates were high because no DOTS incentives, such as free
transportation to and from DOTS facilities, were offered (Nathanson, et al., 2006).
Patient incentives such as free treatment for DOTS appear to be one of the reasons
that cure rates were so high in Nathanson’s study. In the countries in which patient
incentives were offered, there was increased patient compliance (decreased default rates). In
the countries where there were no incentives, patient compliance decreased. While those
incentives may have been offered for study purposes, they are not offered for general
treatment. Also, outside of scientific studies, patients must pay for transportation to and from
DOTS facilities. In some places, patients live so far away from a DOTS facility that they
also must pay for lodging and food for the duration of the treatment. For a subsistence
farmer, this may be too high of a price to pay. If patients do not understand that in order for
treatment to be effective they must take the entire drug regimen for six or more months, those
in developing countries might start treatment but have to stop when they run out of funds.
This pattern increases the incidence of drug-resistant TB because the treatment is not
completed. Once the patient has MDR TB their treatment is even less affordable because the
treatment regimen is even longer (Nathanson, et al., 2006). Thankfully, in many countries the
government pays for TB treatment. This can cause problems because developing nations do
not have enough money to spend on TB treatment, resulting in intermittent drug supply,
contributing to TB resistance. It is a vicious cycle.
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The same drugs that are being used to treat TB today are the same ones that have
been used for the past 30 years (Salomon et al., 2006). These drugs are highly toxic, and the
mycobacteria they attempt to kill are becoming more and more resistant. Why haven’t
newer, more efficient drugs been researched and developed to extinguish TB around the
world? The sad answer is that there is not a fortune to be made by pharmaceutical companies
to research and develop new TB drugs. Since the majority of TB patients live in low to
middle-income countries, they would not be able to pay for an expensive new drug, even if it
was more effective and less toxic. Even if the governments of each nation paid for the new
drug treatment as some do now, it would still be too expensive, because developing nations
cannot afford to pay a lot of money for TB treatment. Without this financial incentive,
pharmaceutical companies and researchers have turned to the development of more profitable
drugs for other diseases, leaving TB patients without alternatives. In the cases of those with
MDR or XDR TB, this also leaves patients without treatment.
Ridley, Grabowski, and Moe proposed an idea to help give incentives to
pharmaceutical researchers in the United States to develop new and more effective TB drugs.
They proposed that vouchers be given to pharmaceutical companies who develop FDAapproved drugs for TB which are superior to the existing drugs. Also, in order to receive a
voucher, the company would have to forgo patent rights and find a manufacturer for the drug.
The vouchers given to the companies for their newly developed TB drugs would be
auctioned to major pharmaceutical companies. Each voucher would give its bearer a
“priority pass” – enabling one of the drugs that they are developing to “cut in line” so to
speak, and go through the FDA’s red tape more quickly (cutting down the time it would take
before that drug hit the market from 18 to six months). This would be profitable (and
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therefore an attractive offer) for the buyer of the voucher because the more time a drug
spends on the market, the more money the company makes. The company holding the
voucher would have to pay a user fee in addition to the amount for which they bought the
voucher. This user fee would cover the cost of the FDA hiring more people, buying more
equipment, etc. required to prioritize that drug (2006).
Vaccinations
The traditional vaccine for TB is the Bacillus Calmete-Guérin (BCG). The BCG
vaccine was developed in the early 1900’s and its use was widespread in France in the late
1920’s. In the 1980’s however, it was discovered that TB caused more deaths in AIDS
patients (especially those who had been vaccinated with the BCG vaccine) than did any other
disease.
Surprisingly, the BCG vaccine was found to be more effective against leprosy
(caused by Mycobacterium leprae) than against TB. Kumar, Malhota, and Goswami
concluded that the BCG vaccine appears to be more effective against systemic mycobacterial
infection than against local pulmonary TB infection (2003).
An alternative to the live attenuated BCG vaccine is the auxotrophic BCG vaccine.
The bacteria in this vaccine are genetically mutated so that they lack the ability to replicate
for very long. These bacteria do not suppress the host immune system (the attenuated
vaccine does), so they can be safely administered to AIDS patients. The drawback is that the
mutated bacteria only last a few months and after that the immunity is lost.
Several ideas about TB vaccines are being explored. Live TB mycobacteria have the
ability, once they enter a host, to suppress its immune system. Little is known about how
they accomplish this. If scientists could discover and isolate the part of the mycobacterium
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that triggers, but does not suppress the immune response, they could use this in the
development of a vaccine against M. tuberculosis. Another vaccine option being explored is
a DNA vaccine. This could be dangerous though because it could cause mutation in the antitumor portion of DNA and allow uncontrolled tumor growth (Kumar, Malhotra, Goswami, &
Bamezai, 2003).
HIV/AIDS And Its Effect On Tuberculosis Treatment
The HIV-infected population is remarkably more vulnerable to TB when compared to
the general population. These immunosuppressed patients are six times more likely to
become infected with tuberculosis in the first year of contraction with HIV, and rates only
increase from there. If an HIV patient develops an active tuberculosis infection they are 100
times more likely to progress to full-blown AIDS. TB is one of the main causes of death in
AIDS patients (Silversides, 2006). Fully one third of those with HIV are co-infected with
TB. The two diseases have a reciprocal relationship. HIV increases susceptibility to TB, and
TB increases the pathogenicity of HIV (Chen, 2004). Treatment of TB in HIV patients is
complicated. As a result of their immunocompromised status, HIV patients’ immune
systems cannot aid the drugs in fighting the TB invasion. Treatment must continue for
several months longer than it would with patients not infected with HIV. Drug interactions
are also highly problematic. Rifampin and rifabutin increase the metabolism of NNRTI’s
(HIV drugs). As a result, this combination of TB and HIV drugs cannot be taken together.
Whichever drug type is chosen (HIV or TB) results in the other condition not receiving
optimal treatment (Lenhe 2007). Some people advocate that using drugs for TB prophylaxis
while also always testing for TB and HIV will help relieve the HIV/TB co-infection crisis
(Silversides, 2006).
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The Incidence Of Tuberculosis In Healthcare Workers
Joshi, Reingold, Menzies, & Pai proposed that in low and middle-income countries,
healthcare workers lack the resources to prevent nosocomial infection of TB (2006). In
researching past studies on this subject, they found that an average of 54% of healthcare
workers have a latent TB infection (69 – 5,780 per 100,000 workers). In contrast, in highincome countries, the incidence of TB in healthcare workers was less than 25 in 100,000 per
year. This could be partly due to the increased number of TB carriers in the general
population in low and middle-income countries as compared to high-income ones. The
presence of latent TB infection in lower-level nursing/medical students in the studies
surveyed correlated with the TB rate of the general population in their respective countries.
Several studies focused on nursing and medical students and found that senior-level students
had two to three times higher rates of latent TB infection than junior-level students.
Therefore, the more time spent in the patient care setting, the more likely a student was to
have a latent TB infection. Correspondingly, in the general healthcare worker population, the
more years spent working in healthcare, the higher the prevalence of TB. In addition, the
jobs with more patient contact (nurses, paramedics, lab technicians, and physicians) had a
higher incidence of TB than those with low patient contact (administrative staff) (Joshi, et al.,
2006).
Low-income countries, because of their limited resources and high incidence of TB,
focus those resources on detection and DOTS treatment of TB. Prevention of healthcare
worker infection is not part of the budget. In high-income settings, the rate of TB in
healthcare workers has been shown to decrease when infection control methods are
implemented. The conclusion that Joshi, et al. came to is that TB is an occupational risk for
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healthcare workers in low to middle-income countries due to high exposure and insufficient
infection control methods (2006).
Ethical Implications
The development of drugs for tuberculosis has been gaining more attention recently
than it had in the past, but publicity alone is not enough to cause pharmaceutical companies
to develop drugs to cure this disease. Tuberculosis is very much a disease of poverty.
Healthcare has become a commodity sold to the highest bidder. This is not an ethical way to
view healthcare. As one nurse researcher put it, “to abandon medical ethics to the
marketplace would be to abandon the meaning of illness, and the trust on which healing is
based” (Benner, 1998, p. 122).
Any disease that affects less than 200,000 Americans is labeled an orphan disease - it
is essentially a disease that is rare in the United States. This narrow definition does not take
into account that a so-labeled orphan disease could be highly prevalent in other areas of the
world. In fact, many “orphan diseases” are diseases of poverty that are rampant in low and
middle-income countries. For years these orphan diseases such as tuberculosis were
practically ignored in the realm of pharmaceutical research and development (R&D) (Towse
& Kettler, 2005, World Health Organization).
In order to help counteract this neglect, the US Orphan Drug Act (ODA) was put into
effect in 1983. In the ODA, the US government recognized that if any pharmaceutical
company tried to develop a drug for an orphan disease, it would result in financial loss for
that company. The ODA uses “push” and “pull” mechanisms to give pharmaceutical
companies incentives to develop drugs for diseases that normally would not be profitable
enough for them to even consider developing. Some examples of the “push” mechanism are
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providing grants to defray the costs of developing the drug, tax breaks, and expedited drug
approval by the FDA. The “pull” mechanism is identified as a period of seven years of
exclusive rights for that drug on the market. The push mechanism is fairly effective, and new
drugs have been developed for some diseases of poverty as a result of this mechanism.
The problem with TB is that it has recently lost its orphan disease status because it
now has infected slightly over 200,000 people in the United States. This is unfortunate,
because when it was an orphan disease pharmaceutical companies could get governmentprovided incentives to develop drugs to treat it. Now, they will not get those incentives, and
since it is so close to the orphan disease cutoff there are still not nearly enough people in
developed nations to justify formulating new TB drugs.
Even if TB dropped back to orphan disease status, there are still problems with the
pharmaceutical incentives provided. Although the push mechanisms are fairly effective in
providing incentives for the development of orphan drugs, the pull mechanism is not a very
effective incentive for the research and development (R&D) of drugs for diseases of poverty.
Seven years of exclusive rights to sell a drug to a poverty-stricken population is not
profitable to a pharmaceutical company for the very reason that the country is poor, and thus
would not be able to afford high drug prices. The current pull mechanism of ODA does
nothing to increase the buying power of the people who need the drug. Towse and Kettler
suggest that governments should set a purchase price for each new drug developed that
would take into account the amount of time spent developing the drug, the cost of developing
the drug, and the cost of failed tries in the process. This would provide an extremely strong
push mechanism, making a poor pull mechanism not as significant a deterrent for
pharmaceutical companies (Towse & Kettler, 2005, Food and Drug Administration, 2007).
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In addition to examining the biological and economic issues of the R&D of TB drugs,
the spiritual and ethical issues involved need to be discussed. Some questions arise, such as
why should people in the United States care about diseases of poverty that affect so few
people in the US? In order to focus on tuberculosis and why the development of new drugs
is essential, this paper promotes the premise that the Bible is the infallible word of God and
thus is true. Each human is a created being who, bearing the image of his or her creator, has
worth in the eyes of God. Genesis 1:27 says, “So God created man in his own image, in the
image of God he created him; male and female he created them.” Since all humans have
worth in the eyes of God, their lives should also have worth in the eyes of believers and
followers of Jesus. Christians are also challenged to follow the words of Christ and care for
the ones who need treatment the most but can’t afford it (the “least of these” – Matthew 25:
40). The fact that some individuals do not have money to pay for the treatment of their
disease should not exclude them from obtaining treatment.
Nurse theorist Patricia Benner emphasizes a need for strangers who are
compassionate to one another. She points out that many people, when reading the story of
the Good Samaritan (Luke 10:25-37), tend to view the story with themselves playing the role
of the Samaritan. Benner goes on to suggest that this thought should be reversed, and that
people should instead imagine themselves as the wounded man, lying on the side of the road
in desperate need of help. Those with tuberculosis and other diseases of poverty are like the
man on the side of the road. The fact that someone can identify with the suffering man
should spur that person to act compassionately and care for those in need – for example, by
working to convince pharmaceutical companies to develop new TB drugs. Each person
hopes that someday when they are suffering, someone will care for them. That common
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human feeling should cause people to care for others who are presently suffering (Benner,
1998).
In the case of drug R&D, money is power. Benner (1998) states that, “Those who are
powerful are able to demand that others care for them” (p. 124). In the high-tech world of
modern medicine, there is a tendency to focus on healthcare as a commodity. Pharmaceutical
companies, which have obligations to their shareholders, look for the R&D projects that will
bring the most profit. R&D for new TB drugs would be a very risky financial maneuver.
Developing drugs for diseases that are prevalent in rich nations is more likely to be
profitable, because those are the ones that have health insurance companies that can afford to
buy drugs at high prices.
The worldwide impact of TB is difficult for Americans to grasp because there are so
few people in the US that have the disease. Though tuberculosis affects millions worldwide,
but it has been placed in the same category as rare cancers that affect only a few thousand
Americans. Americans should care about tuberculosis treatment because the drug-resistant
strains have tremendous potential to spread to developed nations, increasing the number of
untreatable cases in the US. MDR and XDR TB are on the rise, and there are few to no drugs
that can treat these strains.
Current Status
The same drugs that were being used to treat TB decades ago are still being used
today. Despite new discoveries about medicine and technology no new TB drugs have been
developed in the last 30 years. The drugs currently used to treat tuberculosis are not very
effective, and thus have a long course of treatment. They also have unpleasant side effects
and are toxic to many body organs. If people stop taking the medicine because they lack
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funds, because of the unpleasant side effects, or because of the long course of treatment, the
risk that the TB bacteria will develop drug resistance is increased. This has been a common
scenario over the last few decades of TB treatment. Multi-drug resistant TB has become
more and more prevalent in the world. Once a person has contracted multi-drug resistant TB,
other (second-line) drugs must be used. These drugs are even more toxic, more expensive,
and have an even longer course of treatment. This further decreases patient compliance with
taking the medicine and increased mortality rates (Spigelman & Gillespie, 2006; Global TB
Alliance, 2007).
In addition to multi-drug resistant TB, there is now a strain of TB (XDR) that is
resistant to almost every TB drug, making it virtually untreatable. New drugs need to be
developed that are capable of treating this new form of TB and the original form as well.
New drugs need to be developed because this virtually untreatable disease – XDR TB –
could spread across country borders and become epidemic in the US and the rest of the world
(Global TB Alliance, 2007).
The threat of spreading extensively drug resistant TB is a very real and frightening
threat. Previously it was thought that drug resistant TB could be contained in developing
countries and not affect the United States. Then, in the spring of 2007, a man infected with
extensively drug resistant TB traveled to Europe and back to the US; exposing everyone on
the planes and in the airports he was in to the threat of his disease. Fortunately, he did not
transmit it to anyone that the center for disease control (CDC) is aware of, but the threat of
exposure during air travel is there. As previously mentioned, people who have AIDS are
especially susceptible to TB because their immune systems are already compromised. It is
also difficult to treat TB along with AIDS because of the incompatibility of TB and HIV
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drugs. Countries where AIDS is already a problem could be overwhelmed with tuberculosis
if a more effective treatment is not found soon (World Health Organization).
Several organizations have been formed in the past decade to publicize the need for
and facilitate the development of new TB vaccines and drugs. The Global Alliance for TB
Drug Development (Global Alliance) is one of the front-runners of this movement. Their
main goal is to discover and develop new drugs that will shorten the duration of and simplify
TB treatment, improve the treatment of latent TB, and effectively combat multi-drug resistant
TB and extensively drug resistant TB. The Global Alliance is using private companies
partnered with and funded by public entities in adherence with the ODA. These agencies
work to get contracts granting reduced sale prices for the newly developed drugs that would
be affordable for the impoverished people to whom the drugs would be marketed (Wheeler &
Berkley, 2001).
In conclusion, as one of the largest causes of mortality in the world, tuberculosis has
been gaining more publicity in recent years. With the emergence of MDR and XDR TB, it
has become a threat not only to impoverished developing nations, but also to rich developed
nations. If no treatment for drug resistant TB is found, it could spread and become an
epidemic in the US. New drugs need to be developed that shorten drug therapy, are less
toxic, and are affordable to the impoverished people that tuberculosis strikes.
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